Navigation Links
Assay Designs(TM) Announces Collaboration with Medical University of South Carolina (MUSC)

ANN ARBOR, Mich., May 5 /PRNewswire/ -- Assay Designs, Inc., a leading provider of immunoassay kits, antibodies, and reagents to the life sciences and translational research markets, announced a collaboration on a joint antibody research project with the Medical University of South Carolina and Dr. Jennifer Isaacs' laboratory. Under the terms of this agreement, Assay Designs will provide anti-Heat shock protein 90 (Hsp90) antibody for both cell-based and animal-based work.

This collaboration agreement will allow Dr. Isaacs to move forward with research investigating the role of Hsp90 in the progression of many cancers. "I am excited about the prospect of utilizing this antibody to target the Hsp90 chaperone and to potentially curtail the metastatic properties of some cancers. Moreover, we now have a new tool to explore the role of cell surface localized Hsp90 protein in cancer progression. Since this antibody is well-tolerated in animals, this approach paves the way for a promising therapeutic strategy, " stated Dr. Isaacs.

"As the leader in heat shock proteins (HSPs) and chaperones, collaborations such as this provide valuable insight for our new product development efforts," stated Dan Calvo, Assay Designs' President and CEO. "Supporting the validation of new and novel test protocols enhances the value and flexibility of our broad HSP product portfolio."

About Assay Designs, Inc.

Based in Ann Arbor, MI, Assay Designs develops, manufactures and markets immunoassay (ELISA) kits, antibodies, and proteins that are used for life sciences research. The company markets these products under the "Assay Designs" and "Stressgen" brand names. Researchers use Assay Designs products to detect and quantify molecules that are important biomarkers of inflammation, heat shock, cell signaling, and oxidative stress.

About Isaacs Lab.

A long-term research goal of the Isaacs Lab is to better understand the role of Hsp90 in tumor progression to ultimately optimize the use and potency of Hsp90 inhibitors in the clinic. In particular, the lab investigates how Hsp90 contributes to angiogenic processes and cell migration, representing two fundamental and universal aspects of cancer progression. Specifically, the tumor-promoting roles of Hsp90 are being assessed in various invasive cancers, such as prostate, renal cell carcinoma (RCC), and the deadly disease glioblastoma (GBM). Clinically relevant orthotopic models of RCC and GBM are being used and newer forms of Hsp90 antagonists are being evaluated. In collaboration with other groups, there is also interest in identifying combination treatments most effective against these cancers.

SOURCE Assay Designs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics
2. Genetic Engineering & Biotechnology News reports on growing use of cell-based assays
3. Genetic Engineering & Biotechnology News Reports on Growing Use of Cell-Based Assays
4. Cellix Ltd. Launches VenaEC Biochip for Flow-based Cell-adhesion Assays
5. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
6. Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
7. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
8. Cellix Ltd. Launches the First Semi-Automated, High Throughput Cell-Adhesion Assay Platform
9. A New, Unique and Unrivalled Rat/Mouse PINP Assay for Pharmaceutical, Clinical and Academic Research Organizations.
10. Study Reaffirms Superiority of Trofile(TM) Assay
11. EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference
Post Your Comments:
(Date:11/25/2015)... 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... and CEO of Neurocrine Biosciences, will be presenting at ... New York . .   ... approximately 5 minutes prior to the presentation to download ... presentation will be available on the website approximately one ...
(Date:11/25/2015)... November 25, 2015 The ... is a professional and in-depth study on the ...      (Logo: ) , ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ...
(Date:11/24/2015)... Calif. , Nov. 24, 2015 Cepheid ... will be speaking at the following conference, and invited ... New York, NY      Tuesday, December 1, 2015 ... New York, NY      Tuesday, December 1, 2015 ... Jaffray Healthcare Conference, New York, NY ...
(Date:11/24/2015)... ... 24, 2015 , ... International Society for Pharmaceutical Engineering (ISPE) ... annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference took place in ... largest number of attendees in more than a decade. , “The 2015 ...
Breaking Biology Technology:
(Date:11/19/2015)... , Nov. 19, 2015  Although some 350 companies ... dominated by a few companies, according to Kalorama Information. These ... 51% of the market share of the 6.1 billion-dollar ... The World Market for Molecular Diagnostic s .    ... market is still controlled by one company and only ...
(Date:11/17/2015)... Paris , qui s,est tenu ... Paris , qui s,est tenu du 17 au ... l,innovation biométrique, a inventé le premier scanner couplé, qui ... même surface de balayage. Jusqu,ici, deux scanners étaient nécessaires, ... digitales. Désormais, un seul scanner est en mesure de ...
(Date:11/12/2015)... 2015  A golden retriever that stayed healthy despite ... has provided a new lead for treating this muscle-wasting ... Institute of MIT and Harvard and the University of ... Cell, pinpoints a protective gene that ... effects. The Boston Children,s lab of Lou Kunkel ...
Breaking Biology News(10 mins):